biotech · Generalized Myasthenia Gravis · Leukemia, Myeloid, Acute · VOR
Vor Biopharma
Vor Biopharma is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker VOR. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Leukemia, Myeloid, Acute, Systemic Lupus
Cambridge, USA HQ
110 Employees
Public company Type
VOR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 110
- Programs
- 6
- Drugs
- 4
- Patents
- 12
Telitacicept
Phase 3 · mab · Generalized Myasthenia Gravis
Telitacicept for Generalized Myasthenia Gravis is a Phase 3 program (mab) at Vor Biopharma with 1 ClinicalTrials.gov record(s).
Internal code RC18G006
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vor Biopharma
- Phase
- Phase 3
- Modality
- mab
- Indication
- Generalized Myasthenia Gravis
- Status
- active
- Trials
- 1